[1] Gilca GE, Stefanescu G, Badulescu O, et al.Diabetic cardiomyopathy: current approach and potential diagnostic and therapeutic targets[J]. J Diabetes Res, 2017,2017:1310265. [2] Frati G, Schirone L, Chimenti I, et al. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy[J].Cardiovasc Res, 2017, 113(4):378. [3] 张亚楠,孙锋英,王月敏,等.丹红注射液对糖尿病合并冠心病患者胰岛素抵抗、内皮功能、炎症因子、心血管事件的影响[J].河北医科大学学报,2020,41(3):282. [4] 胡洋,潘韵铮,李庆菊,等.丹酚酸B通过抑制NLRP3炎症小体priming阶段减轻缺氧诱导大鼠心肌细胞损伤[J].中国药理学通报,2020,36(2):210. [5] Li YM, Wang LL, Dong ZH, et al. Cardioprotection of salvianolic acid B and ginsenoside Rg1 combination on subacute myocardial infarction and the underlying mechanism[J]. Phytomedicine,2019,57:255. [6] 王娜,隋海娟,符丽娟.丹酚酸B对高糖诱导心肌成纤维细胞增殖及转分化的作用研究[J].中国药理学通报,2020,36(3):414. [7] Feng PP, Fang XS, Zhao SH, et al, Salvianolic acid B decreases interleukin-1β-induced colitis recurrence in mice[J]. Chin Med J, 2020,133(12):1436. [8] 吴元洁, 吴元波, 郑书国, 等. 糖尿病大鼠血糖波动模型的建立[J]. 南方医科大学学报, 2014, 34(6):771. [9] 左斌.甘精胰岛素联合阿卡波糖对2型糖尿病患者胰岛功能和血糖波动的影响[J].临床合理用药杂志,2017,10(27):39. [10] Ma RCW. Epidemiology of diabetes and diabetic complications in China[J].Diabetologia,2018, 61(6):1249. [11] Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013[J]. JAMA, 2017, 317(24):2515. [12] Cavalot F. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes[J]. Diabetes Obesity Meteb, 2013, 15(s2):3. [13] Kim MK, Jung HS, Yoon CS, et al. The effect of glucose fluctuation on apoptosis and function of INS-1 pancreatic beta cells[J]. Korean Diabetes J,2010,34(1):47. [14] Dawson AJ, Sathyapalan T, Atkin SL. Biological variation of cardiovascular risk factors in patients with diabetes[J]. Diabet Med, 2013,30(10):1172. [15] 李雪莲,李智洋,李宾公,等.槲皮素抑制糖尿病大鼠炎症小体激活并减轻心肌损伤[J].中国病理生理杂志,2019,35(8):1345. [16] Karasawa T, Takahashi M. Role of NLRP3 inflammasomes in atherosclerosis[J]. J Atheroscler Thromb, 2017, 24(5): 443. [17] Luo BB, Huang F, Liu YL, et al. NLRP3 Inflammasome as a Molecular Marker in Diabetic Cardiomyopathy[J]. Front Physiol, 2017, 2017:00519. [18] 蒋丹露,刘阳阳,孙如愚,等.NLRP3炎症小体介导的炎症相关疾病研究进展[J].生命科学,2017,29(9):898. [19] Luo BB, Li B, Wang WK, et al. NLRP3 gene silencingameliorates diabetic cardiomyopathy in a type 2 diabetes rat model[J]. PLoS One, 2014, 9(8):e104771. |